The MPN Research Foundation is reaching out to the MPN patient community to raise awareness about an opportunity for patients who live in California, 18 years of age or older with primary myelofibrosis (PMF). Patients who qualify can support research by providing a one-time blood donation from home. The blood sample will be collected by a… Read More »CALLING ALL CALIFORNIA MF PATIENTS!
The MPN Research Foundation has released its Fall 2020 newsletter! You can find your copy of the newest edition of the MPN Update linked to the button below. We hope you enjoy the update on the Patient-Focused Drug Development meeting with FDA, our article welcoming Kapila Viges to the MPNRF team, the clinical trial highlights,… Read More »MPNRF’S FALL 2020 NEWSLETTER IS NOW AVAILABLE!
With your support, The MPN Research Foundation has aided in research that has resulted in a better understanding of Polycythemia Vera, Essential Thrombocythemia, and Myelofibrosis. A recent article titled “Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells” was published in the scientific journal Nature and is partially funded by MPNRF and our supporters. According to Dr. Vijay G. Sankaran,… Read More »NEW MPN ARTICLE PUBLISHED IN THE SCIENTIFIC JOURNAL NATURE
The MPN Research Foundation has been made aware that there is discussions about the COVID-19 (Coronavirus) outbreak and Interferon. Some papers published years ago have been shared in some of the online myeloproliferative neoplasms communities, out of the context of this current outbreak. We urge patients to follow their doctors’ orders regarding their use of… Read More »Coronavirus and interferon
The MPN Research Foundation is proud to announce the appointment of Kapila Viges as the Chicago, IL-based nonprofit’s new Executive Director. Through MPN research, advocacy, and education, the MPN Research Foundation brings together patients, researchers, and clinicians around the common goal of realizing new treatments and, ultimately, a cure for polycythemia vera, essential thrombocythemia, and… Read More »THE MPN RESEARCH FOUNDATION ANNOUNCES NEW EXECUTIVE DIRECTOR
September provides the MPN community a unique opportunity to draw attention to polycythemia vera, essential thrombocythemia, and myelofibrosis by celebrating nationally recognized Blood Cancer Awareness Month (BCAM). This September is especially important because two MPNRF board members have come forward and offered to MATCH all donations made this month dollar-for-dollar up to $10,000! This is an excellent opportunity for our community to… Read More »BLOOD CANCER AWARENESS MONTH HAS ARRIVED!
MPNRF is asking patients to provide personal experience and insights on two topics: Telehealth and Clinical Trials. If you are interested in assisting, please send an email to myMPN@mpnrf.org with the subject line “Telehealth and Clinical Trial Insights” with your response to the following: Are you a participant in a clinical trial or have you considered participation in 2020? If… Read More »TELEHEALTH AND CLINICAL TRIAL INSIGHTS
A review article was recently published by Sebastien Jacquelin et al, covering the history and important contributions of mouse models to our understanding of myeloproliferative neoplasms. Preclinical models such as those described in this manuscript have provided important information about the impact of primary driver gene dosage and the role of secondary genetic mutations as… Read More »CONTRIBUTIONS OF MOUSE MODELS IN UNDERSTANDING MPNS
Great news in upcoming therapies for myeloproliferative neoplasms! Australia based pharmaceutical company, Pharmaxis Limited has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for a planned phase 1/2 study of PXS-5505 for the treatment of myelofibrosis. “This IND submission incorporates the pre-IND feedback Pharmaxis received from the FDA… Read More »INVESTIGATIONAL NEW DRUG SUBMITTED TO THE FDA FOR THE TREATMENT OF MF
